FY2025 EPS Estimate for Krystal Biotech Decreased by Analyst

Krystal Biotech, Inc. (NASDAQ:KRYS) – Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Krystal Biotech in a research note issued to investors on Wednesday, May 7th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings of $4.85 per share for the year, down from their previous forecast of $6.22. Cantor Fitzgerald currently has a “Overweight” rating and a $215.00 price objective on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million.

Several other research firms have also issued reports on KRYS. Citigroup upped their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. HC Wainwright reiterated a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 6th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective for the company. Guggenheim decreased their target price on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Chardan Capital reissued a “buy” rating and set a $219.00 price target on shares of Krystal Biotech in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $218.63.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $132.23 on Friday. Krystal Biotech has a 52-week low of $131.71 and a 52-week high of $219.34. The stock has a market cap of $3.82 billion, a price-to-earnings ratio of 44.22 and a beta of 0.79. The firm’s 50-day moving average is $171.56 and its 200-day moving average is $170.04.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in KRYS. Norges Bank acquired a new position in Krystal Biotech during the 4th quarter worth approximately $34,391,000. Soleus Capital Management L.P. raised its position in Krystal Biotech by 65.2% in the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock valued at $56,144,000 after purchasing an additional 141,400 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Krystal Biotech by 50,249.4% during the first quarter. GAMMA Investing LLC now owns 121,342 shares of the company’s stock valued at $21,878,000 after purchasing an additional 121,101 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Krystal Biotech during the fourth quarter worth about $15,989,000. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Krystal Biotech by 16.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company’s stock valued at $79,812,000 after buying an additional 71,200 shares during the period. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).